2. Signaling Pathways
  3. Neuronal Signaling
  4. Choline Kinase
  5. Choline Kinase Inhibitor

Choline Kinase Inhibitor

Choline Kinase Isoform Comparison

Choline Kinase Inhibitors (11):

Cat. No. Product Name Effect Purity
  • HY-101144
    RSM-932A
    		Inhibitor 98.77%
    RSM-932A (TCD-717) is a specific ChoKα inhibitor with IC50s of 1 and 33 μM for human recombinant ChoKα and ChoKβ enzymes, respectively. RSM-932A acts as the “first in humans” compound targeting ChoKα. RSM-932A is potent in vitro anti-proliferative and in vivo anti-tumoral activity against human xenografts in mice, showing high efficacy with low toxicity profiles.
  • HY-120337
    V-11-0711
    		Inhibitor 98.54%
    V-11-0711 is a potent and selective Chk-α (IC50 = 20 nM) inhibitor. V-11-0711 can significantly reduce PCho levels. V-11-0711 causes a reversible growth arrest. V-11-0711 induces apoptosis at high concentrations. V-11-0711 can be used for the study of cervical cancer and triple-negative breast cancer.
  • HY-170805
    UNC0737
    		Inhibitor 99.70%
    UNC0737 is an orthosteric choline kinase inhibitor. UNC0737 is also a poor inhibitor of G9a (IC50 = 5000 nM) and GLP (IC50 > 10000 nM) in the SAHH-coupled assays.
  • HY-122675
    ACG416B
    		Inhibitor 98.99%
    ACG416B (compound 18) is a potent inhibitor of ChoK (choline kinase) with an IC50 of 0.4 μM. ACG416B renders higher ChoK inhibitory and antiproliferative activities against the HT-29 human colon cancer cell.
  • HY-120337B
    cis-V-11-0711
    		Inhibitor
    cis-V-11-0711 is the cis form of V-11-0711 (HY-120337). V-11-0711 is a potent and selective Chk-α (IC50 = 20 nM) inhibitor. V-11-0711 can significantly reduce PCho levels. V-11-0711 causes a reversible growth arrest. V-11-0711 induces apoptosis at high concentrations. V-11-0711 can be used for the study of cervical cancer and triple-negative breast cancer.
  • HY-120337A
    V-11-0711 hydrochloride
    		Inhibitor
    V-11-0711 hydrochloride is a potent and selective Chk-α (IC50 = 20 nM) inhibitor. V-11-0711 hydrochloride can significantly reduce PCho levels. V-11-0711 hydrochloride causes a reversible growth arrest. V-11-0711 induces apoptosis at high concentrations. V-11-0711 hydrochloride can be used for the study of cervical cancer and triple-negative breast cancer.
  • HY-101145
    CK37
    		Inhibitor
    CK37 is a competitive choline kinase-α inhibitor. CK37 inhibits purified recombinant human choline kinase-α activity. CK37 suppresses MAPK and PI3K/AKT signaling, disrupts actin cytoskeletal organization. CK37 diminishs activating phosphorylations of ERK. CK37 exhibits anticancer activity against cervical cancer, melanoma, Lewis lung carcinoma, lung adenocarcinoma, breast cancer, and leukemia.
  • HY-162799
    ChoKα inhibitor-6
    		Inhibitor
    ChoKα inhibitor-6 (compound Fa22) is a less specific ChoKα1 inhibitor with antitumor activity.
  • HY-123612
    JAS239
    		Inhibitor
    JAS239 is a blood-brain barrier-permeable ChoK inhibitor. JAS239 inhibits phosphocholine synthesis and reduces the expression level of E2F1 protein. JAS239 exhibits near-infrared fluorescence properties. JAS239 exerts anti-tumor activity against glioblastoma. JAS239 can be used in studies related to glioblastoma.
  • HY-101144R
    RSM-932A (Standard)
    		Inhibitor
    RSM-932A (Standard) is the analytical standard of RSM-932A (HY-101144). This product is intended for research and analytical applications. RSM-932A (TCD-717) is a specific ChoKα inhibitor with IC50s of 1 and 33 μM for human recombinant ChoKα and ChoKβ enzymes, respectively. RSM-932A acts as the “first in humans” compound targeting ChoKα. RSM-932A is potent in vitro anti-proliferative and in vivo anti-tumoral activity against human xenografts in mice, showing high efficacy with low toxicity profiles.
  • HY-114081A
    Hemicholinium chloride
    		Inhibitor
    Hemicholinium chloride (HC-3) is a choline kinase (ChoK) inhibitor. Hemicholinium chloride Hemicholinium chloride induces ataxia and muscular weakness.